Gotowa bibliografia na temat „Vascular endothelial growth factor-receptor 2”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Vascular endothelial growth factor-receptor 2”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Vascular endothelial growth factor-receptor 2"
Jackson, Tanisha A., Harry E. Taylor, Deva Sharma, Stephen Desiderio i Sonye K. Danoff. "Vascular Endothelial Growth Factor Receptor-2". Journal of Biological Chemistry 280, nr 33 (7.06.2005): 29856–63. http://dx.doi.org/10.1074/jbc.m500335200.
Pełny tekst źródłaZhao, B., G. Smith, J. Cai, A. Ma i M. Boulton. "Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2". British Journal of Ophthalmology 91, nr 4 (30.08.2006): 538–45. http://dx.doi.org/10.1136/bjo.2006.101543.
Pełny tekst źródłaHu, Xue-Ming, Wei Yang, Li-Xia Du, Wen-Qiang Cui, Wen-Li Mi, Qi-Liang Mao-Ying, Yu-Xia Chu i Yan-Qing Wang. "Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer". Anesthesiology 131, nr 5 (1.11.2019): 1125–47. http://dx.doi.org/10.1097/aln.0000000000002916.
Pełny tekst źródłaNico, Beatrice, Patrizia Corsi, Angelo Vacca, Luisa Roncali i Domenico Ribatti. "Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 expression in mdx mouse brain". Brain Research 953, nr 1-2 (październik 2002): 12–16. http://dx.doi.org/10.1016/s0006-8993(02)03219-5.
Pełny tekst źródłaDing, Yangyang, Kai Liu, Xinyu Zhao, Yingtao Lv, Rilei Yu i Congmin Kang. "Design, synthesis, and antitumor activity of novel benzoheterocycle derivatives as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase". Journal of Chemical Research 44, nr 5-6 (20.01.2020): 286–94. http://dx.doi.org/10.1177/1747519819899067.
Pełny tekst źródłaGuo, Shanchun, Laronna S. Colbert, Miles Fuller, Yuanyuan Zhang i Ruben R. Gonzalez-Perez. "Vascular endothelial growth factor receptor-2 in breast cancer". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1806, nr 1 (sierpień 2010): 108–21. http://dx.doi.org/10.1016/j.bbcan.2010.04.004.
Pełny tekst źródłaSallmon, Hannes, Sandra Akanbi, Sven C. Weber, Alexander Gratopp, Cornelia Rheinländer i Petra Koehne. "Ibuprofen and indomethacin differentially regulate vascular endothelial growth factor and its receptors in ductus arteriosus endothelial cells". Cardiology in the Young 28, nr 3 (4.12.2017): 432–37. http://dx.doi.org/10.1017/s1047951117002311.
Pełny tekst źródłaJanvier, Annie, Sophie Nadeau, Johanne Baribeau i Thérèse Perreault. "Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung". Critical Care Medicine 33, nr 4 (kwiecień 2005): 860–66. http://dx.doi.org/10.1097/01.ccm.0000159563.97092.a7.
Pełny tekst źródłaPedersen, H. G., J. Greenaway, T. Greve i J. Petrik. "248EXPRESSION AND LOCALIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 IN EQUINE FOLLICLES". Reproduction, Fertility and Development 16, nr 2 (2004): 244. http://dx.doi.org/10.1071/rdv16n1ab248.
Pełny tekst źródłaMandriota, Stefano J., Pierre-Alain Menoud i Michael S. Pepper. "Transforming Growth Factor 1 Down-regulates Vascular Endothelial Growth Factor Receptor 2/flk-1Expression in Vascular Endothelial Cells". Journal of Biological Chemistry 271, nr 19 (10.05.1996): 11500–11505. http://dx.doi.org/10.1074/jbc.271.19.11500.
Pełny tekst źródłaRozprawy doktorskie na temat "Vascular endothelial growth factor-receptor 2"
Ruch, Claudia. "Structure / function analysis of the extracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2) /". Zürich : ETH/PSI, 2007. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=17030.
Pełny tekst źródłaJellbauer, Stefan. "Tumorvakzinierung gegen den "Vascular Endothelial Growth Factor Receptor 2" (VEGFR2)mittels heterologem Antigentransport durch rekombinante Salmonellen". Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-120905.
Pełny tekst źródłaIizuka, Takumi. "Vascular endothelial growth factor receptor 3 (VEGFR3) expression in the mouse uterus during decidualization /". Available to subscribers only, 2008. http://proquest.umi.com/pqdweb?did=1650512501&sid=1&Fmt=2&clientId=1509&RQT=309&VName=PQD.
Pełny tekst źródłaHiggins, Kelly Jean. "Regulation of vascular endothelial growth factor receptor-2 in pancreatic and breast cancer cells by Sp proteins". Texas A&M University, 2003. http://hdl.handle.net/1969.1/6010.
Pełny tekst źródłaDeshpande, Abhishek. "Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) and blood vessel density changes in an experimental model of Chronic Hydrocephalus". Kent State University / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=kent1279288736.
Pełny tekst źródłaKwan, Joanne. "Induction of tumor proliferation and metastasis by expression of vascular endothelial growth factor receptor 2 in prostate carcinomas". Thesis, Boston University, 2012. https://hdl.handle.net/2144/12462.
Pełny tekst źródłaVascular endothelial growth factor receptor 2 (VEGFR2) was first discovered on the cells of blood vessels, and has thus been referred to as an endothelial receptor. However, recent evidence suggests that some tumor cells may express VEGFR2 as well. We examine the function of the lowly metastatic human prostate cancer cell line PC3M and its highly metastatic lymph node variant PC3M-LN4. We discovered that PC3M-LN4 cells express high levels of VEGFR2. In vivo, PC3M-LN4 tumors are larger, more metastatic, and more vascularized than PC3M tumors. To further demonstrate the function of VEGFR2, PC3M cells were transfected with a VEGFR2 plasmid and G418 resistant cells were selected then grown as clones. PC3M-VEGFR2 cells were analyzed by Western blot analysis, a migration assay, and a proliferation assay. Cells expressing high levels of VEGFR2 were selected through Western blotting. A Transwell migration assay examining PC3M-VEGFR2.28 revealed greater cell migration towards VEGF-treated media as compared to VEGF-untreated media. A proliferation assay for this same clone showed greater cell proliferation with increasing concentrations of VEGF in both SF and 1% FBS media. These data suggest a direct relationship between VEGFR2 expression and tumor proliferation and metastasis. Furthermore, we noticed that an elongated cell morphology may be a characteristic of metastatic cells. Immunohistochemical analysis of prostate cancer patient biopsies reveals VEGFR2 expression on both tumor cells and endothelial cells. Interestingly, we noticed that this expression is heterogeneous between different patients and even varies within the same biopsy. Our data suggests that anti-VEGFR2 therapies may target both the tumor and blood vessels to inhibit prostate cancer disease progression in those patients that express the receptor.
王, 英泰. "Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells". Kyoto University, 2001. http://hdl.handle.net/2433/150200.
Pełny tekst źródłaMagnusson, Peetra. "Fibroblast Growth Factor Receptor-1 Function in Vasculo- and Angiogenesis". Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5824.
Pełny tekst źródłaCheluvappa, Rajkumar. "Pathophysiology of Liver Sinusoidal Endothelial Cells". Thesis, The University of Sydney, 2008. http://hdl.handle.net/2123/2802.
Pełny tekst źródłaCheluvappa, Rajkumar. "Pathophysiology of Liver Sinusoidal Endothelial Cells". University of Sydney, 2008. http://hdl.handle.net/2123/2802.
Pełny tekst źródłaOwing to its strategic position in the liver sinusoid, pathologic and morphologic alterations of the Liver Sinusoidal Endothelial Cell (LSEC) have far-reaching repercussions for the whole liver and systemic metabolism. LSECs are perforated with fenestrations, which are pores that facilitate the transfer of lipoproteins and macromolecules between blood and hepatocytes. Loss of LSEC porosity is termed defenestration, which can result from loss of fenestrations and/ or decreases in fenestration diameter. Gram negative bacterial endotoxin (Lipopolysaccharide, LPS) has marked effects on LSEC morphology, including induction LSEC defenestration. Sepsis is associated with hyperlipidemia, and proposed mechanisms include inhibition of tissue lipoprotein lipase and increased triglyceride production by the liver. The LSEC has an increasingly recognized role in hyperlipidemia. Conditions associated with reduced numbers of fenestrations such as ageing and bacterial infections are associated with impaired lipoprotein and chylomicron remnant uptake by the liver and consequent hyperlipidemia. Given the role of the LSEC in liver allograft rejection and hyperlipidemia, changes in the LSEC induced by LPS may have significant clinical implications. In this thesis, the following major hypotheses are explored: 1. The Pseudomonas aeruginosa toxin pyocyanin induces defenestration of the LSEC both in vitro and in vivo 2. The effects of pyocyanin on the LSEC are mediated by oxidative stress 3. Defenestration induced by old age and poloxamer 407 causes intrahepatocytic hypoxia and upregulation of hypoxia-related responses 4. Defenestration of the LSEC seen in old age can be exacerbated by diabetes mellitus and prevented or ameliorated by caloric restriction commencing early in life
Książki na temat "Vascular endothelial growth factor-receptor 2"
Duman, Ronald S. Neurotrophic Mechanisms of Depression. Redaktorzy Dennis S. Charney, Eric J. Nestler, Pamela Sklar i Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0027.
Pełny tekst źródłaBadimon, Lina, i Gemma Vilahur. Atherosclerosis and thrombosis. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0040.
Pełny tekst źródłaAlharbi, Yousef, Manish S. Patankar i Rebecca J. Whelan. Antibody-Based Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0006.
Pełny tekst źródłaBadimon, Lina, i Gemma Vilahur. Atherosclerosis and thrombosis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199687039.003.0040_update_001.
Pełny tekst źródłaBadimon, Lina, i Gemma Vilahur. Atherosclerosis and thrombosis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199687039.003.0040_update_002.
Pełny tekst źródłaCzęści książek na temat "Vascular endothelial growth factor-receptor 2"
Marmé, Dieter. "Vascular Endothelial Growth Factor". W Encyclopedia of Cancer, 1–3. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_6155-2.
Pełny tekst źródłaShibuya, M., N. Ito i L. Claesson-Welsh. "Structure and Function of Vascular Endothelial Growth Factor Receptor-1 and -2". W Current Topics in Microbiology and Immunology, 59–83. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59953-8_4.
Pełny tekst źródłaTonra, James R., Marie Prewett, Erik Corcoran, Daniel J. Hicklin i Zhenping Zhu. "In Vivo Method for Establishing Synergy Between Antibodies to Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2". W Therapeutic Antibodies, 545–57. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_30.
Pełny tekst źródłaPaz, Keren, i Zhenping Zhu. "Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy". W Topics in Medicinal Chemistry, 333–82. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/7355_2006_009.
Pełny tekst źródłaFerrara, Napoleone, John E. Park, Claire E. Walder, Stuart Bunting i G. Roger Thomas. "The Regulation of Normal and Pathological Angiogenesis by Vascular Endothelial Growth Factor". W Cardiovascular Disease 2, 133–44. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1959-1_18.
Pełny tekst źródłaZheng, Yongqiang, Jianfen Wei, Xiaojun Li, Ling Xue i Guoyu Qiao. "Detection of Serum Vascular Endothelial Growth Factor (VEGF) and Endothelin, in Type 2 Diabetic Nephropathy Patients and Its Clinical Significance". W Lecture Notes in Electrical Engineering, 1387–92. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-2169-2_165.
Pełny tekst źródłaFerrario, Angela, i Charles J. Gomer. "Targeting the Tumor Microenvironment Using Photodynamic Therapy Combined with Inhibitors of Cyclooxygenase-2 or Vascular Endothelial Growth Factor". W Methods in Molecular Biology, 121–32. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-697-9_9.
Pełny tekst źródłaLugano, Roberta, Hua Huang i Anna Dimberg. "Vascular Endothelial Growth Factor Receptor (VEGFR)". W Encyclopedia of Signaling Molecules, 5884–92. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-67199-4_101914.
Pełny tekst źródłaTaipale, J., T. Makinen, E. Arighi, E. Kukk, M. Karkkainen i K. Alitalo. "Vascular Endothelial Growth Factor Receptor-3". W Current Topics in Microbiology and Immunology, 85–96. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59953-8_5.
Pełny tekst źródłaLugano, Roberta, Hua Huang i Anna Dimberg. "Vascular Endothelial Growth Factor Receptor (VEGFR)". W Encyclopedia of Signaling Molecules, 1–9. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4614-6438-9_101914-1.
Pełny tekst źródłaStreszczenia konferencji na temat "Vascular endothelial growth factor-receptor 2"
Mitsunaga, Makoto, Takashi Nishimura i Kimihiro Ito. "Abstract 5767: Vascular endothelial growth factor receptor 2 targeted photoimmunotherapy". W Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5767.
Pełny tekst źródłaChandler, Kevin B., Deborah R. Leon, Rosana D. Meyer, Nader Rahimi i Catherine E. Costello. "Abstract 1808: Vascular endothelial growth factor receptor-2 (VEGFR-2)N-glycosylation modulates angiogenic signaling". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1808.
Pełny tekst źródłaKubo, Toshio, Kadoaki Ohashi, Masahiro Osawa, Hiromasa Takeda, Eiki Ichihara, Takashi Ninomiya, Nagio Takigawa i in. "Abstract 3681: Vascular endothelial growth factor receptor tyrosine kinase inhibitor inhibited mutated epidermal growth factor receptor-driven tumors ex vivo and in vivo". W Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3681.
Pełny tekst źródłaZebda, Noureddine, Tiffany Ho, Nurgul Moldobaeva, Anna Birukova, Judith A. Berliner i Konstantin G. Birukov. "Involvement Of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) In Oxidized Phospholipid-Mediated Control Of Endothelial Barrier Function". W American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1974.
Pełny tekst źródłaCerri, Elisa, Sonal Kashyap, Pei Xian Chen, Soma Das, Nicole Cipriani, Rajani Kanteti, Aliya Husain, Ravi Salgia i Federico Innocenti. "Abstract 2176: Vascular endothelial growth factor receptor-2 (VEGFR-2) gene variations in bronchioloalveolar cell carcinoma (BAC)". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2176.
Pełny tekst źródłaAlekperov, R., E. Alexandrova, A. Novikov i L. Ananyeva. "AB0798 Clinical associations of vascular endothelial growth factor and its receptor 2 type in systemic sclerosis". W Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4064.
Pełny tekst źródłaLee, You Mie, Jiyoon Seok, Soo-Hyun Yoon, Sun-Hee Lee i Jong Hwa Jung. "Abstract 188: The oncometabolite d-2-hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-188.
Pełny tekst źródłaLee, You Mie, Jiyoon Seok, Soo-Hyun Yoon, Sun-Hee Lee i Jong Hwa Jung. "Abstract 188: The oncometabolite d-2-hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-188.
Pełny tekst źródłaKim, Hee Sung, Hye Seung Lee i Woo Ho Kim. "Abstract 5576: pmTOR and vascular endothelial growth factor receptor (VEGFR)-2 expressions in gastroenteropancreatic neuroendocrine tumors (GEP-NETs)". W Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5576.
Pełny tekst źródłaMorss, Alisa, Michael Jonas i Elazer R. Edelman. "Elevated Basement Membrane Fibroblast Growth Factor-2 Protects Endothelial Cells in High Glucose". W ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-176187.
Pełny tekst źródłaRaporty organizacyjne na temat "Vascular endothelial growth factor-receptor 2"
Li, Ting, Shudan Ge, Wei Zheng, Chao Luan, Xingtong Liu, Zongxiu Luo, Qi Zhao i Lulu Xie. Effectiveness and safety of panretinal photocoagulation combined with intravitreous ranibizumab for patients with type 2 proliferative diabetic retinopathy:A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, kwiecień 2022. http://dx.doi.org/10.37766/inplasy2022.4.0048.
Pełny tekst źródłaTan, Linlin, Zhijie Wang, Yuchun Ni, Fupeng Zhang, Zhaowei Huang, Zhipeng Zhang, Jiaqi Yan i Mei Wu. The efficacy and safety of vascular endothelial growth factor receptor (VEGFR ) inhibitors for recurrent ovarian cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2021. http://dx.doi.org/10.37766/inplasy2021.2.0019.
Pełny tekst źródła